Voltage-gated calcium channels provide an alternate route for iron uptake in neuronal cell cultures

Neurochemical Research

Volumn 32, Issue 10, 2007, Pages 1686-1693

  Gaasch, Julie A ^a   Geldenhuys, Werner J ^b   Lockman, Paul R ^a   Allen, David D ^b   Van Der Schyf, Cornelis J ^b,c  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^c NORTH WEST UNIVERSITY   (South Africa)

Author keywords

Alzheimer's disease; Iron overload toxicity; Neurodegeneration; Nimodipine; Parkinson's disease; Voltage gated calcium channels

Indexed keywords

4 (2 BENZYLBENZOYL) 2,5 DIMETHYL 1H PYRROLE 3 CARBOXYLIC ACID METHYL ESTER; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM ION; IRON; NERVE GROWTH FACTOR; NIMODIPINE; VOLTAGE GATED CALCIUM CHANNEL;

ANIMAL CELL; ARTICLE; CALCIUM TRANSPORT; CELL DEATH; DEGENERATIVE DISEASE; DOSE RESPONSE; IRON TRANSPORT; NERVE CELL CULTURE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BLOTTING, WESTERN; CALCIUM; CALCIUM CHANNEL AGONISTS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CELLS, CULTURED; DATA INTERPRETATION, STATISTICAL; ELECTROPHYSIOLOGY; ION CHANNEL GATING; IRON; NEURONS; NIMODIPINE; PC12 CELLS; PHENOTYPE; PYRROLES; RATS;

MURINAE; RATTUS;

EID: 34548767817     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11064-007-9313-1     Document Type: Article

References (48)

1. Connor JR, Menzies SL, Burdo JR, Boyer PJ (2001) Iron and iron management proteins in neurobiology. Pediatr Neurol 25:118-129
2. Berg D, Gerlach M, Youdim MBH, Double KL, Zecca L, Riederer P, Becker G (2001) Brain iron pathways and their relevance to Parkinson's disease. J Neurochem 79:225-236
3. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR (2004) Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5:863-873
4. Wagner KR, Sharp FR, Ardizzone TD, Lu A, Clark JF (2003) Heme and iron metabolism: role in cerebral hemorrhage. J Cerebr Blood Flow Metab 23:629-652
5. Palmer C, Menzies SL, Roberts RL, Pavlick G, Connor JR (1999) Changes in iron histochemistry after hypoxic-ischemic brain injury in the neonatal rat. J Neurosci Res 56:60-71
6. Umbreit JN, Conrad ME, Moore EG, Latour LF (1998) Iron absorption and cellular transport: the mobilferrin/paraferritin paradigm. Semin Hematol 35:13-26
7. Moos T, Morgan EH (2004) The metabolism of neuronal iron and its pathogenic role in neurological disease: review. Ann N Y Acad Sci 1012:14-26
8. Qian ZM, Shen X (2001) Brain iron transport and neurodegeneration. Trends Mol Med 7:103-108
9. Connor JR, Menzies SL, St Martin S, Mufson E (1990) Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains. J Neurosci Res 27:595-611
10. Kissel K, Hamm S, Schulz M, Vecchi A, Garlanda C, Engelhardt B (1998) Immunohistochemical localization of the murine transferrin receptor (TfR) on blood-tissue barriers using a novel anti-TfR monoclonal antibody. Histochem Cell Biol 110:63-72
11. Dickinson TK, Connor JR (1998) Immunohistochemical analysis of transferrin receptor: regional and cellular distribution in the hypotransferrinemic (hpx) mouse brain. Brain Res 801:171-181
12. Bradbury MW (1997) Transport of iron in the blood-brain-cerebrospinal fluid system. J Neurochem 69:443-454
13. Aisen P, Wessling-Resnick M, Leibold EA (1999) Iron metabolism. Curr Opin Chem Biol 3:200-206
14. Dickinson TK, Connor JR (1995) Cellular distribution of iron, transferrin, and ferritin in the hypotransferrinemic (Hp) mouse brain. J Comp Neurol 355:67-80
15. Moos T, Trinder D, Morgan EH (2000) Cellular distribution of ferric iron, ferritin, transferrin and divalent metal transporter 1 (DMT1) in substantia nigra and basal ganglia of normal and beta2-microglobulin deficient mouse brain. Cell Mol Biol (Noisy-le-grand) 46:549-561
16. 2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med 9:1187-1194
17. Crowe S, Bartfay WJ (2002) Amlodipine decreases iron uptake and oxygen free radical production in the heart of chronically iron overloaded mice. Biol Res Nurs 3:189-197
18. Scriabine A, Van den Kerckhoff W (1988) Pharmacology of nimodipine. A review. Ann N Y Acad Sci 522:698-706
19. 2+ channel activator, in cardiac and vascular preparations. Mol Pharmacol 40:734-741
20. 2+ channel activators, (S)-Bay K 8644 and FPL 64176, in smooth muscle. Mol Pharmacol 41:599-602
21. 2+ channel activator, FPL 64176, in GH3 cells. Mol Pharmacol 42:666-670
22. Calderon FH, Bonnefont A, Munoz FJ, Fernandez V, Videla LA, Inestrosa NC (1999) PC12 and neuro 2a cells have different susceptibilities to acetylcholinesterase-amyloid complexes, amyloid25-35 fragment, glutamate, and hydrogen peroxide. J Neurosci Res 56:620-631
23. 2+ channels in rat phaeochromocytoma cell lines. J Physiol 426:95-116
24. Garber SS, Hoshi T, Aldrich RW (1989) Regulation of ionic currents in pheochromocytoma cells by nerve growth factor and dexamethasone. J Neurosci 9:3976-3987
25. Powers JF, Evinger MJ, Tsokas P, Bedri S, Alroy J, Shahsavari M, Tischler AS (2000) Pheochromocytoma cell lines from heterozygous neurofibromatosis knockout mice. Cell Tissue Res 302:309-320
26. Wu GS, Vaswani KK, Lu ZH, Ledeen RW (1990) Gangliosides stimulate calcium flux in neuro-2A cells and require exogenous calcium for neuritogenesis. J Neurochem 55:484-491
27. Herman MD, Reuveny E, Narahashi T (1993) The effect of polyamines on voltage-activated calcium channels in mouse neuroblastoma cells. J Physiol 462:645-660
28. Carlson RO, Masco D, Brooker G, Spiegel S (1994) Endogenous ganglioside GM1 modulates L-type calcium channel activity in N18 neuroblastoma cells. J Neurosci 14:2272-2281
29. Liu L, Gonzalez PK, Barrett CF, Rittenhouse AR (2003) The calcium channel ligand FPL 64176 enhances L-type but inhibits N-type neuronal calcium currents. Neuropharmacol 45:281-292
30. McDonough SI, Mori Y, Bean BP (2005) FPL 64176 modification of Ca(V)1.2 L-type calcium channels: dissociation of effects on ionic current and gating current. Biophys J 88:211-223
31. Becker G, Seufert J, Bogdahn U, Reichmann H, Reiners K (1995) Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography. Neurology 45:182-184
32. Berg D, Hochstrasser H, Schweitzer KJ, Riess O (2006) Disturbance of iron metabolism in Parkinson's disease - ultrasonography as a biomarker. Neurotox Res 9:1-13
33. Faucheux BA, Martin ME, Beaumont C, Hauw JJ, Agid Y, Hirsch EC (2003) Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease. J Neurochem 86:1142-1148
34. Jurma OP, Hom DG, Andersen JK (1997) Decreased glutathione results in calcium-mediated cell death in PC12. Free Radic Biol Med 23:1055-1066
35. Sofic E, Riederer P, Heinsen H, Beckmann H, Reynolds GP, Hebenstreit G, Youdim MB (1988) Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 74:199-205
36. Bishop GM, Robinson SR, Liu Q, Perry G, Atwood CS, Smith MA (2002) Iron: a pathological mediator of Alzheimer disease? Dev Neurosci 24:184-187
37. Castellani RJ, Smith MA, Nunomura A, Harris PL, Perry G (1999) Is increased redox-active iron in Alzheimer disease a failure of the copper-binding protein ceruloplasmin? Free Radic Biol Med 26:1508-1512
38. Yagami T, Ueda K, Sakaeda T, Itoh N, Sakaguchi G, Okamura N, Hori Y, Fujimoto M (2004) Protective effects of a selective L-type voltage-sensitive calcium channel blocker, S-312-d, on neuronal cell death. Biochem Pharmacol 67:1153-1165
39. Zapater P, Moreno J, Horga JF (1997) Neuroprotection by the novel calcium antagonist PCA50938, nimodipine and flunarizine, in gerbil global brain ischemia. Brain Res 772:57-62
40. Rinkel GJ, Feigin VL, Algra A, Van den Bergh WM, Vermeulen M, van Gijn J (2005) Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst. Rev.: CD000277
41. Robinson MJ, Teasdale GM (1990) Calcium antagonists in the management of subarachnoid haemorrhage. Cerebrovasc Brain Metab Rev 2:205-226
42. Wadworth AN, McTavish D (1992) Nimodipine. A review of its pharmacological properties, and therapeutic efficacy in cerebral disorders. Drugs Aging 2:262-286
43. Hakim AM, Evans AC, Berger L, Kuwabara H, Worsley K, Marchal G, Biel C, Pokrupa R, Diksic M, Meyer E (1989) The effect of nimodipine on the evolution of human cerebral infarction studied by PET. J Cereb Blood Flow Metab 9:523-534
44. Kajikawa H, Ohta T, Yoshikawa Y, Funatsu N, Yamamoto M, Someda K (1979) Cerebral vasospasm and hemoglobins - clinical and experimental studies. Neurol Med Chir (Tokyo) 19:61-71
45. Gutteridge JM (1987) The antioxidant activity of haptoglobin towards haemoglobin-stimulated lipid peroxidation. Biochim Biophys Acta 917:219-223
46. Regan RF, Panter SS (1993) Neurotoxicity of hemoglobin in cortical cell culture. Neurosci Lett 153:219-222
47. 2+ channel modifiers: possible implications in iron overload. Circ Res 84:1302-1309
48. Mwanjewe J, Hui BK, Coughlin MD, Grover AK. (2001) Treatment of PC12 cells with nerve growth factor increases iron uptake. Biochem J 357:881-886